HART Appoints Laura Mondano as Vice President of Regulatory Affairs To Lead HART's 2016 IND Submission For its Bioengineered Organ Implant Solutions

Categories
About this Disease New Findings

Harvard Apparatus Regenerative Technology (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, announced today that Laura Mondano has joined the company as Vice President of Regulatory Affairs, a new position at HART
http://www.prnewswire.com/news-releases/hart-appoints-laura-mondano-as-vice-president-of-regulatory-affairs-to-lead-harts-2016-ind-submission-for-its-bioengineered-organ-implant-solutions-300229895.html